United States Head and Neck Cancer Therapeutics Market, By Type (Diagnostic Methods (Biopsy, Imaging, Endoscopy, and Others), Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, and Targeted Therapy)), By Disease Indication (Lip & Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, and Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, and Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) By Region, Competition, Forecast and Opportunities, 2028

United States head and neck cancer therapeutics market is expected to grow at an impressive rate during the forecast period, 2024-2028 owing to the rising incidence rates of head and neck cancer, technological advancements, focus on immunotherapy, collaborative research efforts, increased awareness, and supportive regulatory and reimbursement policies.

The rising incidence of head and neck cancer in the United States is one of the primary drivers fueling the market expansion. The increase in incidents has been attributed to a number of causes due to tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, and exposure to specific occupational hazards. Advanced therapies have been introduced as a result of research and development efforts driven by the demand for efficient treatment alternatives for combating the problem.

The landscape of head and neck cancer therapeutics has gone through an evolution due to developments in medical technology. New therapeutic options have been made possible by the development of immunotherapies, targeted treatments, and precision medicine techniques. Genomic and molecular tests allow for the creation of personalized treatment programs for each patient, increasing the overall effectiveness of therapeutics. Additionally, improvements in radiation therapy and surgical methods have improved treatment outcomes and decreased side effects, spurring the market expansion.

Proactive programs for screening and increased awareness campaigns have assisted in detecting head and neck cancer early. Early diagnosis allows prompt action, which enhances the effectiveness of treatment. Additionally, campaigns to educate the public have emphasized the significance of risk factor modification, such as quitting smoking and drinking alcohol in moderation, to lower the frequency of preventable instances. The demand for efficient medicines has increased due to the focus on early detection and prevention.

The field of head and neck cancer therapeutics is seeing a growing interest in precision medicine, which involves modifying therapy regimens, based on a patient's genetic profile. Medical professionals may identify precise genetic changes and biomarkers that fuel tumor growth through developments in genomic testing and molecular profiling tools. Tyrosine kinase inhibitors and monoclonal antibodies, which specifically target cancer cells while minimizing harm to healthy organs, can be developed as a result of this information. Precision medicine's rising popularity is predicted to fuel the market by enhancing treatment outcomes and lowering adverse effects.

The field of head and neck cancer therapeutics may undergo a transformation due to the integration of artificial intelligence (AI) and big data analytics. To identify patterns, forecast treatment outcomes, and direct personalized treatment decisions, artificial intelligence can analyze enormous volumes of patient data, including medical records, imaging scans, and genomic profiles. This data-driven strategy has the potential to improve treatment approaches and advance precision medicine. The use of AI and big data analytics in clinical settings will boost the market and enhance patient outcomes.

Patient-centered care and supportive care services have become increasingly important in the treatment of head and neck cancer. Supportive treatment concentrates on treating complications of the drugs, enhancing patients' quality of life, and offering psychosocial support. Incorporating palliative care services to cancer therapy has been found to improve patient satisfaction and treatment compliance. The demand for supportive care services will increase, supporting market expansion as healthcare systems prioritize complete patient care.

There are some challenges that are hampering the growth of United States head and neck cancer therapeutics market. These challenges include high treatment costs, limited options for rare subtypes, resistance to therapy, treatment-related toxicities, regulatory hurdles, and limited awareness.

The cost of treating cancer, including head and neck cancer, appears to be a major issue. Targeted and immunotherapies are examples of novel medicines with substantial price tags. The total costs of these therapies are affected by the high cost of research and development, clinical trials, manufacturing, and distribution.

Significant side effects and toxicities can arise from the severe nature of head and neck cancer treatment, which typically involves surgery, radiation therapy, and chemotherapy. These might involve xerostomia, dysphagia, mucositis, and long-term side effects including persistent pain and swallowing issues. These side effects may have a significant negative influence on patients' functional results and quality of life. To enhance patient experiences and treatment adherence, efforts to minimize toxicities associated with the treatment must be made for the development of supportive care techniques.

Growing Incidences of Head and Neck Cancer

The incidence of head and neck cancer is on the rise worldwide, including in the United States, which is a major threat to public health. To improve treatment outcomes and improve patient care, there has been a lot of research and development due to the rise in cases. The expansion of the head and neck cancer therapeutics market in the United States is influenced by the rising incidence of head and neck cancer. ASCO estimates that 4% of all malignancies in the United States are head and neck cancers. A projected 66,920 individuals (49,190 males and 17,730 women) will be diagnosed with a head and neck cancer in 2023.

The prevalence of head and neck cancer is rising as a result of a number of factors, including tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, and exposure to specific occupational dangers.

Pharmaceutical companies and academic institutions are continually investigating fresh medications and therapeutic approaches to treat head and neck cancer. A few of these developments are precision medicine approaches, targeted drugs, and immunotherapies that are customized to each patient's unique genetic profile and tumor features.

Clinical Trial Status

·      On June 30, 2022, regardless of PD-L1 status, Novartis announced findings from the Phase III RATIONALE 306 trial demonstrating that tislelizumab plus chemotherapy significantly increased overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC).

·      Imfinzi (durvalumab) by AstraZeneca did not succeed in improving overall survival (OS) compared to the EXTREME treatment plan (chemotherapy plus cetuximab), the standard of care, in the KESTREL Phase III trial. These patients had head and neck squamous cell carcinoma (HNSCC) which was recurrent or metastatic and whose tumors had high levels of PD-L1. Additionally, the addition of Imfinzi and tremelimumab did not work to show a benefit for OS in 'all-comer' patients, a secondary goal.

·       On December 7, 2018, AstraZeneca and MedImmune, its worldwide biologics research and development company, released the Phase III EAGLE trial's overall survival (OS) data. Regardless of the patients' PD-L1 tumor status, the EAGLE trial compares Imfinzi (durvalumab) monotherapy or Imfinzi in combination with the anti-CTLA4 antibody tremelimumab to standard-of-care (SoC) chemotherapy for patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) who experienced disease progression after platinum-based chemotherapy.

·         On March 13, 2020, Pfizer Inc. and EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, in the US and Canada, released an update from the Phase III JAVELIN Head and Neck 100 study comparing the effectiveness of avelumab in addition to standard-of-care CRT versus LA SCCHN patients who had not yet received treatment for their disease. The alliance has agreed to the independent Data Monitoring Committee's (DMC) recommendation to end the JAVELIN Head and Neck 100 trial because, according to an anticipated interim analysis, the trial is not likely to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival (PFS).

·      Tecentriq® (atezolizumab) and Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence after liver resection or ablation with curative intent, according to new data from the Phase III IMbrave050 study.

FDA Approvals

• Pembrolizumab (KEYTRUDA, Merck) was given FDA approval on June 10, 2019, to be used as the first-line treatment for people with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). The FDA approved the use of pembrolizumab as a single drug for patients whose tumors express PD-L1 (Combined Positive Score [CPS]] 1 as determined by an FDA-approved test) and in combination with platinum and fluorouracil (FU) for all patients.

Market Segmentation

The United States head and neck cancer therapeutics market can be segmented by type, disease indication, route of administration, therapeutic class, end user, and region. By type, the United States head and neck cancer therapeutics market can be segmented into diagnostic methods and treatment type. Based on diagnostic methods, the United States head and neck cancer therapeutics market is divided into biopsy, imaging, endoscopy, and others. Based on treatment type, the United States head and neck cancer therapeutics market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Based on disease indication, the United States head and neck cancer therapeutics market is divided into lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer. Based on route of administration, the United States head and neck cancer therapeutics market is divided into injectable and oral. Based on therapeutic class, the United States head and neck cancer therapeutics market is divided into PD inhibitors, EGFR inhibitors, and microtubule inhibitors. Based on end user, the United States head and neck cancer therapeutics market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.

 Market Players

Merck & Co., Inc., Bristol Myers Squibb, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc., Amgen Inc., AbbVie Inc., Novartis AG are some of the leading companies operating in the market.

Report Scope:

In this report, United States head and neck cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• United States Head and Neck Cancer Therapeutics Market, By Type
• Diagnostic Methods
• Treatment Type
  
  
• United States Head and Neck Cancer Therapeutics Market, By Disease Indication
• Lip & Oral Cavity Cancer
• Laryngeal Cancer
• Oropharyngeal Cancer
• Salivary Gland Cancer
• Nasopharyngeal Cancer
• Hypopharyngeal Cancer
  
  
• United States Head and Neck Cancer Therapeutics Market, By Route of Administration
• Injectable
• Oral
  
  
• United States Head and Neck Cancer Therapeutics Market, By Therapeutic Class
• PD Inhibitors
• EGFR Inhibitors
• Microtubule Inhibitors
  
  
• United States Head and Neck Cancer Therapeutics Market, By End User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others
  
  

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States head and neck cancer therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).